Drug Shortage Report for HEPARIN SODIUM INJECTION, USP
| Report ID | 154476 |
| Drug Identification Number | 02392453 |
| Brand name | HEPARIN SODIUM INJECTION, USP |
| Common or Proper name | Heparin Sodium Injection, USP 10,000USP units/mL SD Vial 0.5mL |
| Company Name | FRESENIUS KABI CANADA LTD |
| Market Status | MARKETED |
| Active Ingredient(s) | HEPARIN SODIUM |
| Strength(s) | 10000UNIT |
| Dosage form(s) | SOLUTION |
| Route of administration | SUBCUTANEOUS INTRAVENOUS SUBCUTANEOUS INTRAVENOUS |
| Packaging size | 0.5mL |
| ATC code | B01AB |
| ATC description | ANTITHROMBOTIC AGENTS |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | |
| Actual start date | 2022-02-01 |
| Estimated end date | 2022-04-18 |
| Actual end date | 2022-04-04 |
| Shortage status | Resolved |
| Updated date | 2022-04-13 |
| Company comments | Fresenius Kabi Canada regrets to advise that due to a production delay, our Heparin Sodium Injection, USP 10,000USP units/mL SD Vial 0.5mL allocations will be reduced to 50% effective February 1, 2022 and will be on backorder effective March 1, 2022 until April 18, 2022. |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 165 GALAXY BLVD, SUITE 100 TORONTO, ONTARIO CANADA M9W 0C8 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v4 | 2022-04-13 | French | Compare |
| v3 | 2022-04-13 | English | Compare |
| v2 | 2022-02-08 | French | Compare |
| v1 | 2022-02-08 | English | Compare |
Showing 1 to 4 of 4